NASDAQ · VYGR
Healthcare · Biotechnology
$3.05
Down-$0.02 (-0.50%)
Updated Sep 17, 2026, 3:19 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
VYGR closed at $3.05 after 20 trading sessions, down 10.56% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $3.11 | $3.11 | $2.97 | $3.05 | 633.4K |
| Sep 15, 2026 | $3.19 | $3.19 | $3.03 | $3.09 | 452K |
| Sep 14, 2026 | $3.17 | $3.21 | $3.14 | $3.19 | 305.83K |
| Sep 11, 2026 | $3.24 | $3.28 | $3.145 | $3.19 | 276.06K |
| Sep 10, 2026 | $3.20 | $3.22 | $3.13 | $3.19 | 334.5K |
| Sep 9, 2026 | $3.37 | $3.38 | $3.205 | $3.25 | 500.58K |
| Sep 8, 2026 | $3.48 | $3.495 | $3.375 | $3.40 | 488.65K |
| Sep 4, 2026 | $3.34 | $3.515 | $3.3337 | $3.51 | 406.75K |
| Sep 3, 2026 | $3.54 | $3.55 | $3.35 | $3.38 | 619.98K |
| Sep 2, 2026 | $3.43 | $3.585 | $3.43 | $3.54 | 435.03K |
| Sep 1, 2026 | $3.42 | $3.48 | $3.35 | $3.43 | 461.28K |
| Aug 31, 2026 | $3.51 | $3.51 | $3.345 | $3.45 | 395.56K |
| Aug 28, 2026 | $3.47 | $3.555 | $3.36 | $3.54 | 406.27K |
| Aug 27, 2026 | $3.46 | $3.52 | $3.43 | $3.46 | 262.79K |
| Aug 26, 2026 | $3.48 | $3.52 | $3.41 | $3.46 | 279.76K |
| Aug 25, 2026 | $3.45 | $3.56 | $3.45 | $3.48 | 307.58K |
| Aug 24, 2026 | $3.39 | $3.46 | $3.24 | $3.44 | 406.17K |
| Aug 21, 2026 | $3.36 | $3.435 | $3.30 | $3.39 | 424.44K |
| Aug 20, 2026 | $3.39 | $3.40 | $3.20 | $3.32 | 716.95K |
| Aug 19, 2026 | $3.33 | $3.48 | $3.31 | $3.41 | 638.55K |
The latest Smart Investors Daily articles mentioning VYGR.
VYGR research
Company profile and research snapshot.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 10, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 17, 2026 | HC Wainwright & Co. | Buy | — |
| Nov 12, 2025 | HC Wainwright & Co. | Buy | — |
| Sep 15, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 7, 2025 | Wedbush | Outperform | — |
No generated briefing is available yet.
SeekingAlpha · Sep 10, 2026
Voyager Therapeutics, Inc. (VYGR) Wells Fargo 21st Annual Healthcare Conference September 8, 2026 3:45 PM EDTCompany ParticipantsAlfred Sandrock -...
Yahoo · Sep 1, 2026
LEXINGTON, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference: Fireside chat at 3:45 p.m. ET on Tuesday, September 8, 2026, in Boston, MA.2026 Cantor Global Healthcare Conference: Fireside chat at 8:35 a.m. ET on Friday, September 11
Benzinga · Aug 10, 2026
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR) with a Buy and maintains $25 price target.
Benzinga · Aug 6, 2026
Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.48) by 16.67 percent. This is a 29.82 percent increase over losses of $(0.57) per share
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning VYGR.
